55results about How to "Good neutralizing activity" patented technology

The invention belongs to the technical field of biomedicine, and relates to a Clostridium difficile exotoxin A carboxy-terminal gene fragment with an optimized codon and a nucleic acid vaccine thereof. In the gene sequence with the optimized codon, the codon usage biases of mammalian cells and Escherichia coli are considered; and the Clostridium difficile vaccine consists of the exotoxin A carboxy-terminal gene sequence with the optimized codon and a eukaryotic expression vector pJW4303. The Clostridium difficile exotoxin A carboxy-terminal gene fragment with the optimized codon can be used for constructing the nucleic acid vaccine, effectively stimulates an immune system of a host after a mammal is immunized so as to produce better humoral immune response, is also applicable to the prokaryotic expression of a protein in the Escherichia coli, and lays a foundation for the batch acquisition of the protein.

The present invention provides an antibody targeting SARS-CoV-2 and its preparation method and application. The antibody comprises VH and VL, and the VH comprises the following CDRs: VH with amino acid sequence as shown in SEQ ID NO: 1, 2, 3 CDR1, VH CDR2, VH CDR3; the VL comprises the following CDRs: VL CDR1, VL CDR2, VL CDR3 with amino acid sequences as shown in SEQ ID NO: 4, 5, 6. The antibody can bind with high affinity and specificity to the RBD of the S protein of SARS-CoV-2, inhibit the binding of the RBD protein to the receptor ACE2 protein, and efficiently inhibit SARS-CoV-2 from infecting cells, while preventing potential immune escape mutations The pseudovirus has good neutralizing activity, so it can be effectively applied to the diagnosis, prevention and treatment of SARS-CoV-2 virus and related diseases.

This application provides an anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody and its application. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody of the present application comprises three heavy chain complementarity determining regions (CDR‑H1, CDR‑H2 and CDR‑H3) and three light chain complementarity determining regions (CDR‑L1 , CDR‑L2 and CDR‑L3), wherein, (a) the amino acid sequence of CDR‑H1 is shown in SEQ ID NO: 1; (b) the amino acid sequence of CDR‑H2 is shown in SEQ ID NO: 2; (c ) The amino acid sequence of CDR‑H3 is shown in SEQ ID NO: 3; (d) the amino acid sequence of CDR‑L1 is shown in SEQ ID NO: 4; (e) the amino acid sequence of CDR‑L2 is shown in SEQ ID NO: 5 and (f) the amino acid sequence of CDR-L3 is shown in SEQ ID NO:6. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody, compared with the anti-human TSLP monoclonal antibody Tezepelumab (expressed and prepared according to the sequence disclosed in the patent), has comparable affinity for binding human TSLP, and is in the cell level. It is more active than Tezepelumab and is expected to show good clinical effects in the prevention and treatment of related diseases.

This application relates to the anti-H7N9 fully human monoclonal antibody 4E18 and its preparation method and application. A fully human monoclonal antibody 4E18 was rapidly screened by memory B cell PCR without any mouse components. The antibody of the present application can target the hemagglutinin HA of the H7N9 virus, and has a significant neutralizing activity against H7N9 virus infection; the antibody of the present application does not cause toxic and side effects such as anti-mouse anti-antibody, has better biocompatibility, and is more It is suitable and has more potential to become a macromolecular drug for treating influenza virus.